Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 5/20 | 0.32 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.31 |
| ▸ | FSCN1 | Q16658 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4484270 | 0.92 | AKR1B1 (0.32) | AKR1B1FSCN1 | |
| SCHEMBL4487534 | 0.92 | AKR1B1 (0.32) | AKR1B1FSCN1 | |
| SCHEMBL4501531 | 0.91 | AKR1B1 (0.33) | AKR1B1FSCN1 | |
| SCHEMBL4484242 | 0.90 | MEN1 (0.35) | P2RX7MEN1KMT2AALDH1A1LMNA | |
| SCHEMBL4477871 | 0.90 | AKR1B1 (0.31) | AKR1B1 | |
| SCHEMBL4484250 | 0.89 | PDK1 (0.34) | AKR1B1 | |
| SCHEMBL4480516 | 0.89 | LMNA (0.35) | AKR1B1MEN1KMT2AALDH1A1LMNA | |
| SCHEMBL4484029 | 0.89 | OPRM1 (0.34) | P2RX7AKR1B1FSCN1MEN1KMT2A | |
| SCHEMBL4480319 | 0.88 | AKR1B1 (0.35) | AKR1B1FSCN1LMNA | |
| SCHEMBL4489427 | 0.88 | AKR1B1 (0.33) | AKR1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070179196-A1 | Hiv integrase inhibitors | MERCK SHARP & DOHME CORP. | 2007-08-02 | — | — | US | claimed |
| US-7598264-B2 | HIV integrase inhibitors | MERCK & CO., INC. (US) | 2009-10-06 | — | — | US | disclosed |
| US-20070179196-A1 | Hiv integrase inhibitors | MERCK SHARP & DOHME CORP. | 2007-08-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070179196-A1 | Hiv integrase inhibitors | REV1, TYMP, POLR2H | P2RX7 3818/4885AKR1B1 2248/4885FSCN1 4613/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.